Li Li, Chen Bao-An
Department of Hematology (Key Medical Discipline), Zhongda Hospital, Southeast University Medical School, Nanjing, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1289-92.
Burkitt lymphoma is a highly aggressive non-Hodgkin's lymphoma. As Burkitt lymphoma cells are very sensitive to chemotherapy, chemotherapy is the major therapeutic schedule for this disease. Rituximab raised the overall survival rate markedly. Bone marrow transplant, surgery and radiotherapy also demonstrated to have a supporting role for patients with Burkitt lymphoma. This review focus on research progress of the therapeutics and major regimens for the disease.
伯基特淋巴瘤是一种高度侵袭性的非霍奇金淋巴瘤。由于伯基特淋巴瘤细胞对化疗非常敏感，化疗是该疾病的主要治疗方案。利妥昔单抗显著提高了总生存率。骨髓移植、手术和放疗对伯基特淋巴瘤患者也显示出辅助作用。本综述重点关注该疾病的治疗研究进展和主要治疗方案。
